timothy sykes logo

Stock News

Alumis Stock Soars After Phase 3 Trial Success

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 1/11/2026, 11:13 am ET 1/11/2026, 11:13 am ET | 5 min 5 min read
Alumis Stock Soars After Phase 3 Trial Success Thumbnail

Alumis Inc.’s stocks have been trading up by 8.64 percent following FDA designations that bolstered investor confidence.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Alumis (ALMS) is positioned precariously within its market, with significant fiscal challenges. The company’s pretax profit margin stands at a staggering -1364.1, indicative of severe inefficiencies or strategic missteps affecting profitability. Coupled with a -40.01 return on equity, the company has struggled to leverage equity capital effectively. ALMS’ enterprise value of $1.7 billion reflects market recognition of its potential, albeit tempered by its high price-to-sales ratio of 92.26, suggesting overvaluation. Operationally, the free cash flow of -$110.9 million underscores a concerning cash burn, which may necessitate further capital restructuring or strategic pivoting to turn the trajectory positive.

  2. Technical Analysis & Trading Strategy: ALMS has displayed an upward trend in weekly price patterns, with the latest close at $19.75, marking a sustained increase from $11.4 at the start of the observed period. The dominant trend is bullish, with key support established at $17.42 and resistance evident around $19.79. Recent 5-minute candle analysis suggests continued upward momentum, with the potential for a breakout beyond the $19.79 resistance level if volume supports the move. Traders should consider a long position, targeting $21.00, while carefully monitoring any pullback to $18.24 as a potential exit point should the upward trajectory falter.

  3. Catalysts & Outlook: The recent surge in Alumis shares, driven by positive phase 3 trial results for the investigational drug envudeucitinib, highlights a substantial catalyst bolstering investor confidence. This development positions ALMS favorably against broader Healthcare and Biotechnology benchmarks, reflecting its potential to capture market share with an innovative treatment for plaque psoriasis. Based on recent performance and substantial volume surges, ALMS is poised to maintain upward momentum with a near-term price target of $22.00, should the positive clinical outcomes translate into regulatory advancement. Overall, given the transformative potential of its pipeline and recent positive sentiment, Alumis is likely to experience continued investor enthusiasm.

Candlestick Chart

Weekly Update Jan 05 – Jan 09, 2026: On Sunday, January 11, 2026 Alumis Inc. stock [NASDAQ: ALMS] is trending up by 8.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Alumis Inc. recently demonstrated a remarkable surge in stock prices, propelled by encouraging clinical trial results. On January 6, 2026, the stock opened at $16.25, reaching a high of $16.69 before closing at $16.36. The upward trajectory continued in subsequent days, closing at $19.75 on January 9. However, the company’s financials paint a more complex picture. The enterprise value stands at $1.7B, with a daunting price-to-sales ratio of 92.26, indicating high valuation expectations. Financial strength metrics reveal a leverage ratio of 1.3, albeit underlined by a concerning return on equity of -40.01%, suggesting inefficiencies in capital usage.

Recent income statements show a loss with a gross profit of $2.07M against total expenses of $117.36M, leading to a net income deficit of $110.75M. The financial reports further disclose a negative cash flow from operating activities amounting to -$110.91M, highlighting cash challenges. Yet, free cash flow remains negative, reflecting the need for strategic financial planning to capitalize on the drug’s potential market breakthrough.

More Breaking News

Despite these challenges, the triumphant trial of envudeucitinib projects positive future revenue possibilities. Investor optimism hinges on efficient commercialization strategies for envudeucitinib, which could potentially reverse the streak of financial underperformance. Key ratios such as a price-to-tangible book of 6.12 and market anticipation of drug approval have emboldened short-term trading actions.

Conclusion

Alumis finds itself at a pivotal juncture, with envudeucitinib’s success illuminating a path to potential profitability. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This trading wisdom underscores the importance of not succumbing to impulsive actions despite the encouraging signs. While enduring financial strains demand caution, the substantial trader backing evidenced through the stock’s recent ascent emphasizes market belief in future prescription sales growth. Critical fiscal management and strategic drug launches will be central to sustaining this momentum and achieving long-term shareholder value.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”